# Arnatar Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/arnatar-therapeutics

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.arnatar.com
- Total disclosed funding: $66M
- Latest round: Series A (Apr 8, 2024)
- Investors on record: 12

## About

Based in Shanghai, China, and founded in 2022, Arnatar Therapeutics operates as a biopharmaceutical developer that focuses on the development of innovative nucleic acid drugs. The founding team includes Dr. Xuehai Liang, a former Ionis technology leader, and Dr. Yanfeng Wang, a former DMPK and clinical pharmacology leader at Merck, Novartis, and Ionis. In April 2024, Arnatar Therapeutics raised over USD 52 million in series A funding co-led by new investors Eight Roads Ventures, F-Prime Capital, and 3E Bioventures Capital, with participation from other new investors Huajin Capital, Gaorong Ventures, Jifeng Ventures, New Alliance Capital, Yijing Investment, Legend Star, Hongsheng Capital, and Transfar Group. Other unspecified investors also participated in the round, etc. Arnatar Therapeutics is dedicated to the development of innovative drugs for the treatment of liver-targeted and extra-hepatic targeting of nucleic acids, based on antisense technology. The company has developed more than 10 antisense drugs. It has also built the siRNA technology platform and the ASO technology platform, Advanced Antisense Platform, that regulates protein expression in both directions. The drugs can be used in curing common metabolic diseases and severe rare diseases. The company generates revenue by developing antisense drugs. The company will accelerate its drug pipeline and advance clinical trials, as well as the operation of its Chinese company.

## Funding rounds

- Series A, Apr 8, 2024, $52M — Eight Roads Ventures, F-Prime Capital, New Alliance Capital, Gaorong Ventures, Legend Star, 3E Bioventures Capital, Yijing Investment, Transfar Group, Huajin Lingchuang Fund Management, Hongsheng Junhao Investment, Jifeng Ventures
- Seed, Sep 19, 2022, $14M — Apricot Capital

## Investors

- Apricot Capital (https://capitalatlas.ai/funds/apricot-capital) — Seed
- Eight Roads Ventures (https://capitalatlas.ai/funds/eight-roads-ventures) — Series A
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A
- New Alliance Capital (https://capitalatlas.ai/funds/new-alliance-capital) — Series A
- Gaorong Ventures (https://capitalatlas.ai/funds/gaorong-ventures) — Series A
- Legend Star (https://capitalatlas.ai/funds/legend-star) — Series A
- 3E Bioventures Capital (https://capitalatlas.ai/funds/3e-bioventures-capital) — Series A
- Yijing Investment (https://capitalatlas.ai/funds/yijing-investment) — Series A
- Transfar Group — Series A
- Huajin Lingchuang Fund Management (https://capitalatlas.ai/funds/huajin-lingchuang-fund-management) — Series A
- Hongsheng Junhao Investment (https://capitalatlas.ai/funds/hongsheng-junhao-investment) — Series A
- Jifeng Ventures (https://capitalatlas.ai/funds/jifeng-ventures) — Series A